Skip to main content
SpringerLink
Log in

Quantitative changes in cytological molecular markers during primary medical treatment of breast cancer: A pilot study

  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

Aim: To quantify the changes in biological molecular markers during primary medical treatment in patients with operable breast cancer and to assess their possible relationship with response to treatment.

Methods: The treatment group consisted of 31 patients with operable breast carcinomas, median age 57 years (range 41–67), treated with four 3‐weekly cycles of chemotherapy with Mitoxantrone, methotrexate (± mitomycin C), and tamoxifen before surgery. Fine needle aspiration (FNA) was used to obtain samples from patients prior to and at 10 or 21 days post‐treatment. The following molecular markers were assessed: estrogen receptor (ER), progesterone receptor (PgR), p53, Bcl‐2, and Ki67 measured by immunocytochemistry, and ploidy and S‐phase fraction (SPF) by flow cytometry. To evaluate the reproducibility of the technique, repeat FNA was performed in a separate non‐treatment control group of 20 patients and the same molecular markers assessed, two weeks after the first sample with no intervening treatment.

Results: The non‐treatment control group showed a high reproducibility for the measurement of molecular markers from repeat FNA. In the treatment group there was a non‐significant reduction in SPF and a significant reduction (p = 0.005) in Ki67. Patients who responded to neoadjuvant therapy were more likely to have a reduction in these two markers than those who failed to respond. Similarly, a reduction in ER scores was observed between the first and second samples (p = 0.04). For PgR, the change between the first and second samples was not significant although there was a significant difference between responders and non‐responders (p = 0.03). All nine patients with an increase in PgR were responders. No significant changes in p53 or Bcl‐2 were observed during treatment.

Conclusion: Molecular markers can be adequately measured from FNA samples prior to and during neoadjuvant therapy. Changes in cellular proliferation and hormone receptors have been shown that may be related to tumour response. These relationships should be assessed in a larger cohort of patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Powles TJ, Hickish TF, Makris A, Ashley SE, O'Brien MER, Tidy VA, Casey S, Nash AG, Sacks N, Cosgrove D, et al.: Randomized trial of chemoendocrine therapy started before or after surgery for treatment of primary breast cancer. J Clin Oncol 13: 547–552, 1995

    Google Scholar 

  2. Bonadonna G, Veronesi U, Brambilla C, Ferrari L, Luini A, Greco M, Bartoli C, Coopmans de Yoldi G, Zucali R, Rilke F, et al.: Primary chemotherapy to avoid mastectomy in tumors with diameter of three centimeters or more. J Natl Cancer Inst 82: 1539–1545, 1990

    Google Scholar 

  3. Hortobagyi GN, Ames FC, Buzdar AU, Kau SW, Mc-Neese MD, Paulus D, Hug V, Holmes FA, Romsdahl MM, Fraschini G, et al.: Management of stage III primary breast cancer with primary chemotherapy, surgery, and radiation therapy. Cancer 62: 2507–2516, 1988

    Google Scholar 

  4. Scholl SM, Pierga JY, Asselain B, Beuzeboc P, Dorval T, Garcia-Giralt E, Jouve M, Palangie T, Remvikos Y, Durand JC, et al.: Breast tumour response to primary chemotherapy predicts local and distant control as well as survival. Eur J Cancer 31A(12): 1969–1975, 1996

    Google Scholar 

  5. Anderson EDC, Forrest APM, Levack PA, Chetty U, Hawkins RA: Response to endocrine manipulation and oestrogen receptor concentration in large operable breast cancer. Br J Cancer 60: 223, 1989

    Google Scholar 

  6. McGuire WL: The usefulness of steroid receptors in the management of primary and advanced breast cancer. In: Mouridson HT, Palshof T (eds): Breast Cancer: Experimental and Clinical Aspects. New York: Pergammon Press, 1980, pp. 39–43

    Google Scholar 

  7. Scottish Cancer Trials Breast Group and ICRF Breast Unit GH, London: Adjuvant ovarian ablation versus CMF chemotherapy in premenopausal women with pathological stage II breast carcinoma: the Scottish Trial. Lancet 341: 1293–1298, 1993

    Google Scholar 

  8. Howell A, Harland RNL, Barnes DM, Baildam AD, Wilkinson MJS, Hayward E, Swindell R, Sellwood RA: Endocrine therapy for advanced carcinoma of the breast: relationship between the effect of tamoxifen upon concentrations of progesterone receptor and subsequent response to treatment. Cancer Res 47: 300–304, 1987

    Google Scholar 

  9. O'Reilly SM, Camplejohn RS, Rubens RD, Richards MA: DNA flow cytometry and response to preoperative chemotherapy for primary breast cancer. Eur J Cancer 28: 681–683, 1992

    Google Scholar 

  10. Remvikos Y, Jouve M, Beuzeboc B, Viehl P, Magdaelenat H, Pouillart P: Cell cycle modifications of breast cancers during neoadjuvant chemotherapy: a flow cytometry study on fine needle aspirates. Eur J Cancer 29A(13): 1843–1848, 1993

    Google Scholar 

  11. Ellis PA, Detre S, Burton SA, Salter J, Johnston SRD, Smith IE, Dowsett M: Changes in proliferation, apoptosis, and Bcl-2 in breast cancer specimens following neoadjuvant chemotherapy. Breast Cancer Res Treat 37 (suppl.): 36, 1996

    Google Scholar 

  12. Paradiso A, Tommasi S, Mangia A, Lorusso V, Simone G, De Lena M: Tumor-proliferative activity, progesterone receptor status, estrogen receptor level, and clinical outcome of estrogen receptor-positive advanced breast cancer. Cancer Research 50: 2958–2962, 1990

    Google Scholar 

  13. Lowe SW, Ruley HE, Jacks T, Housman DE: p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74: 957–967, 1993

    Google Scholar 

  14. Reed JC: Regulation of apoptosis by bcl-2 family proteins and its role in cancer and chemoresistance. Current Opinion in Oncology 7: 541–546, 1995

    Google Scholar 

  15. Montes A, Powles TJ, O'Brien MER, Ashley SE, Luckitt J, Treleavan J: A toxic interaction between mitomycin C and tamoxifen causing the haemolytic uraemic syndrome. Eur J Cancer 29A: 1854–1857, 1993

    Google Scholar 

  16. Hayward JL, Carbone PP, Heuson JC, Kumaoka S, Segaloff A, Rubens RD: Assessment of response to therapy in advanced breast cancer. Br J Cancer 35: 292–298, 1977

    Google Scholar 

  17. Walker KJ, Bouzubar N, Robertson J, Ellis IO, Elston CW, Blamey RW, Wilson DW, Griffiths K, Nicholson RI: Immunocytochemical localization of estrogen receptor in human breast tissue. Cancer Res 48: 6517–6522, 1988

    Google Scholar 

  18. Allred DC, Bustamante MA, Daniel CO, Gaskill HV, Cruz AB: Immunocytochemical analysis of estrogen receptors in human breast carcinomas. Arch Surg 125: 107–113, 1990

    Google Scholar 

  19. Ormerod MG (ed): Flow cytometry. A practical approach. 2nd edition. Oxford University Press, Oxford, 1994

    Google Scholar 

  20. Makris A, Powles TJ, Dowsett M, Osborne CK, Trott PA, Fernando IN, Ashley SE, Ormerod MG, Titley JC, Gregory RK, et al.: Prediction of response to neoadjuvant chemoendocrine therapy in primary breast carcinomas. Clinical Cancer Research 3: 593–600, 1997

    Google Scholar 

  21. Makris A, Allred DC, Powles TJ, Dowsett M, Fernando IN, Trott PA, Ashley SE, Ormerod MG, Titley JC, Osborne CK: Cytological evaluation of biological prognostic markers from primary breast carcinomas. Breast Cancer Res Treat 44: 65–74, 1997

    Google Scholar 

  22. Fernando IN, Titley JC, Powles TJ, Dowsett M, Trott PA, Ashley SE, Ford HT, Ormerod MG: Measurement of Sphase fraction and ploidy in sequential fine-needle aspirates from primary human breast tumours treated with tamoxifen. Br J Cancer 70: 1211–1216, 1994

    Google Scholar 

  23. Prey MU, Meyer JS, Stone KR. Heterogeneity of breast carcinomas determined by flow cytometric analysis. J Surg Oncol 29: 35–39, 1985

    Google Scholar 

  24. Remvikos Y, Vielh P, Padoy E, et al.: Breast cancer proliferation measured on cytological samples: a study by flow cytometry of S-phase fractions and BrdU incorporation. Br J Cancer 64: 501–507, 1991

    Google Scholar 

  25. Osborne CK, Boldt DH, Estrada P: Human breast cancer cell cycle synchronization by estrogens and antiestrogens in culture. Cancer Res 44: 1433–1439, 1984

    Google Scholar 

  26. Osborne CK, Boldt CH, Clark GM, Trent JM: Effects of tamoxifen on human breast cancer cell cycle kinetics: accumulation of cells in early G1 phase. Cancer Res 43: 3583–3585, 1983

    Google Scholar 

  27. Sarkaria JN, Gibson DFC, Jordan VC, et al.: Tamoxifeninduced increase in the potential doubling time of MCF-7 xenografts as determined by bromodeoxyuridine labeling and flow cytometry. Cancer Research 53: 4413–4417, 1993

    Google Scholar 

  28. Osborne CK, Hobbs K, Clark GM: Effect of estrogens and antiestrogens on growth of human breast cancer cells in athymic nude mice. Cancer Res 45: 584–590, 1985

    Google Scholar 

  29. Clarke RB, Laidlaw IJ, Jones LJ, Howell A, Anderson E: Effect of tamoxifen on Ki67 labelling index in human breast tumours and its relationship to oestrogen and progesterone receptor status. Br J Cancer 67: 606–611, 1993

    Google Scholar 

  30. Johnston SRD, MacLennan KA, Sacks NPM, Salter J, Smith IE, Dowsett M: Modulation of Bcl-2 and Ki67 expression in oestrogen-receptor-positive human breast cancer by tamoxifen. Eur J Cancer 30A(11): 1663–1669, 1995

    Google Scholar 

  31. Rasbridge SA, Gillet CE, Seymour A-M, Patel K, Richards MA, Rubens RD, Millis RR: The effects of chemotherapy on morphology, cellular proliferation, apoptosis and oncoprotein expression in primary breast carcinoma. Br J Cancer 70: 335–341, 1994

    Google Scholar 

  32. Billgren A, Rutqvist LE, Skoog L, Wilking N: Changes of proliferating fraction during neoadjuvant chemotherapy of primary breast cancer as a predictor of objective response. Breast Cancer Research and Treatment 32 (suppl.): 63, 1994

    Google Scholar 

  33. Gardin G, Alama A, Rosso R, Campora E, Repetto L, Merlini L, Naso C, Camoriano A, Meazza R, Barbieri F, et al.: Relationship of variations in tumor cell kinetics induced by primary chemotherapy to tumor regression and prognosis in locally advanced breast cancer. Breast Cancer Res Treat 32: 311–318, 1994

    Google Scholar 

  34. Gorczyca W, Tuziak T, Kram A, Melamed MR, Darzynkiewicz Z: Detection of apoptosis-associated DNA strand breaks in fine-needle aspiration biopsies by in situ end labeling of fragmented DNA. Cytometry 15: 169–175, 1994

    Google Scholar 

  35. Ellis PA, Smith IE, Salter J, Detre S, O'Brien MER, Ramage F, Dowsett M: Pre-operative/neoadjuvant chemotherapy for early breast cancer induces apoptosis. Proc Annu Meet Am Soc Clin Oncol 15: 112, 1996

    Google Scholar 

  36. Skoog L, Rutqvist LE, Wilking N: Analysis of hormone receptors and proliferation fraction in fine-needle aspirates from primary breast carcinomas during chemotherapy or tamoxifen treatment. Acta Oncologica 31(2): 139–141, 1992

    Google Scholar 

  37. Lane DP: p53 and human cancers. British Medical Bulletin 50(3): 582–599, 1994

    Google Scholar 

  38. Dive C, Evans CA, Whetton AD: Induction of apoptosis – new targets for cancer chemotherapy. Semin Cancer Biol 3: 417–427, 1992

    Google Scholar 

  39. Walton MI, Whysong D, O'Connor PM, Hockenbery D, Korsmeyer SJ, Kohn KW: Constitutive expression of human bcl-2 modulates nitrogen mustard and camptothecin induced apoptosis. Cancer Res 53: 1853–1861, 1993

    Google Scholar 

  40. Ohmori T, Podack ER, Nishio K: Apoptosis of lung cancer cells caused by some anti-cancer agents (MMC, CPT-11, ADM) is inhibited by bcl-2. Biochem Biophys Res Commun 192: 30–36, 1993

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Royal Marsden Hospital, Sutton, Surrey, UK

    A. Makris, T.J. Powles & S.E. Ashley

  2. University of Texas Health Science Center, San Antonio, Texas, USA

    D.C. Allred

  3. Royal Marsden Hospital, London, UK

    P.A. Trott & M. Dowsett

  4. ,of Cancer Research, Sutton, Surrey, UK

    M.G. Ormerod

Authors
  1. A. Makris
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. T.J. Powles
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. D.C. Allred
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. S.E. Ashley
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. P.A. Trott
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. M.G. Ormerod
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. M. Dowsett
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Makris, A., Powles, T., Allred, D. et al. Quantitative changes in cytological molecular markers during primary medical treatment of breast cancer: A pilot study. Breast Cancer Res Treat 53, 51–59 (1999). https://doi.org/10.1023/A:1006179511178

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1006179511178

Search

Navigation